Adaptive Biotechnologies CorporationADPT

NASDAQHealthcareBiotechnology$25.51

Price as of Oct 23, 5:00 PM EDT · delayed, not real-time

A clinical-stage biotechnology company developing T-cell receptor-based diagnostics and therapeutics for immune-mediated diseases and cancer. Its immunoSEQ platform and clonoSEQ assay are used in research and minimal residual disease testing, with commercial partnerships including a collaboration with Genentech. Investors track ADPT for its pipeline in personalized cancer vaccines and its diagnostics revenue growth.

52W Range: $12.00-$30.74

Congressional Interest in Adaptive Biotechnologies Corporation (ADPT)

1 member of Congress has disclosed 3 trades in Adaptive Biotechnologies Corporation (ADPT), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.